|Status: One Wales interim decision|
Using the agreed starting and stopping criteria, infliximab can be made available within NHS Wales for the treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other immunosupressants.
Infliximab should be prescribed on the basis of lowest acquisition cost.
The risks and benefits of the off-label use of infliximab for this indication should be clearly stated and discussed with the patient to allow informed consent.
Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.
This advice will be reviewed after 12 months or earlier if new evidence becomes available.
Treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other immunosupressants
|BNF chapter||Respiratory system|
|Submission type||One Wales|
|Status||One Wales interim decision|
|Date of issue||02/03/2023|